Distinguished in Acute Myeloblastic Leukemia with Maturation

Dr. Ellen K. Ritchie

Oncology | Hematology
Weill Medical College Of Cornell
520 E 70th St, 
New York, NY 
Offers Telehealth
Distinguished in Acute Myeloblastic Leukemia with Maturation
Weill Medical College Of Cornell
520 E 70th St, 
New York, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Ellen Ritchie is an Oncologist and a Hematologist in New York, New York. Dr. Ritchie is rated as a Distinguished provider by MediFind in the treatment of Acute Myeloblastic Leukemia with Maturation. Her top areas of expertise are Acute Myeloid Leukemia (AML), Myelofibrosis, Polycythemia Vera, Bone Marrow Aspiration, and Bone Marrow Transplant.

Her clinical research consists of co-authoring 80 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Hematology
Licenses
Internal Medicine in NY
Hospital Affiliations
New York-Presbyterian Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health First
  • HMO
  • POS
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
VNS Health
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

WEILL MEDICAL COLLEGE OF CORNELL
520 E 70th St, New York, NY 10021

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults With Relapsed or Refractory Disease
A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults With Relapsed or Refractory Disease
Enrollment Status: Suspended
Publish Date: September 22, 2025
Intervention Type: Biological
Study Drugs: Blinatumomab, Inotuzumab
Study Phase: Phase 2
A Novel Pediatric-Inspired Regimen With Reduced Myelosuppressive Drugs for Adults (Aged 18-60) With Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia
A Novel Pediatric-Inspired Regimen With Reduced Myelosuppressive Drugs for Adults (Aged 18-60) With Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia
Enrollment Status: Active_not_recruiting
Publish Date: September 16, 2025
Intervention Type: Drug, Device, Other
Study Drugs: Daunorubicin, Vincristine, Prednisone, PEG-Asparaginase, Methotrexate, 6-Mercaptopurine, Cyclophosphamide, Cytarabine, Leucovorin, Dexamethasone
Study Phase: Phase 2
Myeloproliferative Neoplasms (MPN) and COVID-19
Myeloproliferative Neoplasms (MPN) and COVID-19
Enrollment Status: Completed
Publish Date: September 15, 2025
A Phase 2, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)
A Phase 2, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)
Enrollment Status: Completed
Publish Date: July 14, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses
A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses
Enrollment Status: Completed
Publish Date: May 01, 2025
Intervention Type: Drug
Study Drug: Ponatinib
Study Phase: Phase 2
A Phase 3, Multi-center, Open-label, Randomized Study of Oral ABL001 Versus Bosutinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase (CML-CP), Previously Treated With 2 or More Tyrosine Kinase Inhibitors
A Phase 3, Multi-center, Open-label, Randomized Study of Oral ABL001 Versus Bosutinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase (CML-CP), Previously Treated With 2 or More Tyrosine Kinase Inhibitors
Enrollment Status: Completed
Publish Date: April 08, 2025
Intervention Type: Drug
Study Drugs: ABL001, Bosutinib
Study Phase: Phase 3
A Phase 1b Trial of Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Patients With Hematological Malignancies
A Phase 1b Trial of Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Patients With Hematological Malignancies
Enrollment Status: Terminated
Publish Date: January 17, 2025
Intervention Type: Drug
Study Drugs: Magrolimab, Azacitidine
Study Phase: Phase 1
Parallel Phase II Trial of IPA Targeted Adoptive Immunotherapy vs Adult Haplo-identical Cell Infusion During Induction of High Risk Leukemia
Parallel Phase II Trial of IPA Targeted Adoptive Immunotherapy vs Adult Haplo-identical Cell Infusion During Induction of High Risk Leukemia
Enrollment Status: Terminated
Publish Date: February 13, 2024
Intervention Type: Biological
Study Drugs: Haplo-identical cells, Umbilical cord blood unit
Study Phase: Phase 2
A Pilot Study of a Novel Sequential Treatment Utilizing CPX-351 as Salvage Chemotherapy Followed by Allogeneic Stem-Cell Transplantation (SCT) Utilizing a Haplo-cord Graft for Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrome
A Pilot Study of a Novel Sequential Treatment Utilizing CPX-351 as Salvage Chemotherapy Followed by Allogeneic Stem-Cell Transplantation (SCT) Utilizing a Haplo-cord Graft for Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrome
Enrollment Status: Completed
Publish Date: December 21, 2022
Intervention Type: Drug, Biological
Study Drugs: CPX-351, Fludarabine, Melphalan, Rabbit Anti-Human T-Lymphocyte Globulin, Haplo-Cord Stem Cell Transplantation
Study Phase: Phase 1
An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis
An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis
Enrollment Status: Completed
Publish Date: June 16, 2022
Intervention Type: Drug
Study Drugs: Itacitinib, Ruxolitinib
Study Phase: Phase 2
Expanded Access of Pemigatinib to Treat a Single Patient With Metastatic Pancreatic Cancer
Expanded Access of Pemigatinib to Treat a Single Patient With Metastatic Pancreatic Cancer
Enrollment Status: No_longer_available
Publish Date: April 19, 2022
Intervention Type: Drug
Detection, Monitoring, and Molecular Characterization of Leukemic Stem Cells From Patients With Chronic Myeloid Leukemia (CML) Undergoing Therapy With Nilotinib
Detection, Monitoring, and Molecular Characterization of Leukemic Stem Cells From Patients With Chronic Myeloid Leukemia (CML) Undergoing Therapy With Nilotinib
Enrollment Status: Completed
Publish Date: March 25, 2022
Intervention Type: Drug
Study Drug: Nilotinib
Study Phase: Phase 2
A Phase 1b/2 Study to Evaluate the Safety and Efficacy of APR-246 in Combination With Azacitidine for the Treatment of TP53 Mutant Myeloid Neoplasms
A Phase 1b/2 Study to Evaluate the Safety and Efficacy of APR-246 in Combination With Azacitidine for the Treatment of TP53 Mutant Myeloid Neoplasms
Enrollment Status: Completed
Publish Date: January 24, 2022
Intervention Type: Drug
Study Drugs: APR-246, Azacitidine
Study Phase: Phase 1/Phase 2
View 12 Less Clinical Trials

80 Total Publications

Pemigatinib for Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement.
Pemigatinib for Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement.
Journal: NEJM evidence
Published: August 26, 2025
Similar Doctors
Distinguished in Acute Myeloblastic Leukemia with Maturation
Dr. Jamie L. Koprivnikar
Oncology | Hematology
Distinguished in Acute Myeloblastic Leukemia with Maturation
Dr. Jamie L. Koprivnikar
Oncology | Hematology

Regional Cancer Care Associates LLC

30 Prospect Ave, 
Hackensack, NJ 
 (9.8 miles away)
201-996-2210
Languages Spoken:
English
See accepted insurances

Jamie Koprivnikar is an Oncologist and a Hematologist in Hackensack, New Jersey. Dr. Koprivnikar is rated as a Distinguished provider by MediFind in the treatment of Acute Myeloblastic Leukemia with Maturation. Her top areas of expertise are Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Acute Myeloblastic Leukemia without Maturation, Bone Marrow Aspiration, and Endoscopy.

Distinguished in Acute Myeloblastic Leukemia with Maturation
Dr. Michele Donato
Oncology | Hematology
Distinguished in Acute Myeloblastic Leukemia with Maturation
Dr. Michele Donato
Oncology | Hematology

Regional Cancer Care Associates LLC

92 2nd St, 
Hackensack, NJ 
 (9.8 miles away)
201-996-5900
Languages Spoken:
English
See accepted insurances

Michele Donato is an Oncologist and a Hematologist in Hackensack, New Jersey. Dr. Donato is rated as an Elite provider by MediFind in the treatment of Acute Myeloblastic Leukemia with Maturation. Her top areas of expertise are Multiple Myeloma, Graft Versus Host Disease (GvHD), Acute Myeloid Leukemia (AML), Bone Marrow Transplant, and Colonoscopy.

Distinguished in Acute Myeloblastic Leukemia with Maturation
Dr. Eytan M. Stein
Hematology | Oncology
Distinguished in Acute Myeloblastic Leukemia with Maturation
Dr. Eytan M. Stein
Hematology | Oncology

Memorial Hematology Lymphoma Group

530 E 74th St, 
New York, NY 
 (0.2 miles away)
212-639-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Eytan Stein is a Hematologist and an Oncologist in New York, New York. Dr. Stein is rated as an Elite provider by MediFind in the treatment of Acute Myeloblastic Leukemia with Maturation. His top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Myelodysplastic Syndrome (MDS), Bone Marrow Aspiration, and Bone Marrow Transplant.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ritchie's expertise for a condition
ConditionClose
View All 10 Distinguished Conditions
View All 13 Advanced Conditions
View All 28 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile